



Join Keystone Symposia
for the 2016 conference on:

New Therapeutics for Diabetes and Obesity

April 17–20, 2016

Estancia La Jolla Hotel & Spa | La Jolla, CA | USA

Scientific Organizers:

Richard D. DiMarchi, Matthias H. Tschöp and Nancy A. Thornberry

Type 2 diabetes (T2DM) is a global pandemic with approximately 350 million patients worldwide, driven largely by increasing prevalence of obesity. Multiple options exist for treatment of the primary disease and the array of associated cardiovascular disorders. Nonetheless, the majority of patients do not reach recommended glycemic goals, and there is an urgent need for more efficacious, cost-effective and safe therapies. The regulatory hurdle for new drugs is sizable and challenged by the specific requirement for cardiovascular mortality study. Given the magnitude of the challenges, highly collaborative efforts involving academia, biotech, pharma, regulatory agencies, patient advocacy groups and other key stakeholders are required to identify and advance new therapies that are substantially differentiated from current disease management. The major goals of this meeting are to: 1) Define the distance between current therapy relative to what is most needed to address successfully the near-term challenges of the disease and the wave of later-stage disease-specific complications; 2) Communicate the most important scientific advances in metabolic diseases with the intimate details that often escape peer-review publication and are seminal to drug R&D; and 3) Create opportunities for candid discussion among key stakeholders (academia, biotech, industry, regulatory, venture community, etc.) to identify new business processes, along with new science to streamline the successful conversion of ideas to medicines. This meeting meeting will be uniquely led by experienced drug-hunters with world-class academic credentials to help foster the translation of basic science to breakthrough therapeutics.

Session Topics:

- Identification of Breakthrough Therapies for the Treatment of Diabetes and Obesity: Challenges and Opportunities
- New Therapeutics: Late-Breaking Clinical Data
- Novel Insulins and Insulin Action
- Emerging Areas in Drug Discovery
- New Therapeutics in Gut Biology
- New Target Discovery



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Dec 16, 2015

Abstract Deadline: Jan 19, 2016

Discounted Registration Deadline: Feb 16, 2016

For additional details, visit www.keystonesymposia.org/16G1.

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230
a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

New Therapeutics for Diabetes and Obesity (G1)

April 17-20, 2016 • Estancia La Jolla Hotel & Spa • La Jolla, California, USA

Scientific Organizers: Richard D. DiMarchi, Matthias H. Tschöp and Nancy A. Thornberry

Sponsored by Arena Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: December 16, 2015 / Abstract Deadline: January 19, 2016 / Discounted Registration Deadline: February 16, 2016

SUNDAY, APRIL 17

Arrival and Registration

MONDAY, APRIL 18

Welcome and Keynote Address

Joseph L. Goldstein, University of Texas Southwestern Medical Center, USA

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

Identification of Breakthrough Therapies for the Treatment of Diabetes and Obesity: Challenges and Opportunities

Philip Home, Newcastle University, UK

Developing New Therapies for the Management of Type 2 Diabetes

Steven R. Smith, Florida Hospital, USA

Current State of Therapy in Treatment of Obesity

John C. Lechleiter, Eli Lilly and Company, USA

A Century in Diabetes Therapy – With Still More to Do!

Short Talk(s) Chosen from Abstracts

Panel: Perspectives on Future Treatment of Metabolic Diseases and Remaining Unmet Needs

New Therapeutics: Late-Breaking Clinical Data

Speaker to be Announced

Medicinal Approach

Speaker to be Announced

Medicinal Approach

Speaker to be Announced

Non-Conventional Approach, Devices & Surgeries

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, APRIL 19

Novel Insulins and Insulin Action

Richard D. DiMarchi, Indiana University, USA

New Insulin Analogs for the Treatment of Type 2 and Type 2 Diabetes

Mark D. Erion, Merck & Co., Inc., USA

Discovery of Insulin Analogs with Reduced Hypoglycemic Risk

Aaron Kowalski, Juvenile Diabetes Research Foundation

International, USA

Utilizing a Diabetes Scorecard to Guide New Therapeutic Research and Development

Timothy Kieffer, University of British Columbia, Canada

Treating Diabetes with Differentiated Pluripotent Stem Cells

Short Talk(s) Chosen from Abstracts

Emerging Areas in Drug Discovery

Jeffrey M. Friedman, Rockefeller University, USA

CNS Control of Metabolism: New Opportunities

Ronald M. Evans, Howard Hughes Medical Institute, Salk Institute, USA

Nuclear Hormones as a Therapeutic Target

Barbara B. Kahn, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

The Role of Endogenous Lipids in Metabolic Diseases

Umut Ozcan, Children's Hospital Boston, Harvard Medical School, USA

Talk Title to be Announced

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, APRIL 20

New Therapeutics in Gut Biology

Thue W. Schwartz, University of Copenhagen, Denmark

Metabolite Sensors – A Novel Multi-Hormonal Approach to Dial In Efficacy in the Treatment of Obesity and Diabetes

Daniel J. Drucker, Lunenfeld Tanenbaum Research Institute, Canada

New Therapeutic Opportunities in Gut Biology: Balancing Risks and Benefits

Matthias H. Tschöp, Helmholtz Zentrum München and Technische Universität München, Germany

Gut Hormone Based Uni-Molecular Polyagonists

Michael W. Schwartz, University of Washington, USA

Brain Control of Glucose Homeostasis: Implications for Diabetes Treatment

Short Talk(s) Chosen from Abstracts

Panel: Emerging Models for Non-Conventional Approaches to Drug Discovery with an Emphasis on Partnerships

New Target Discovery

Kevin L. Grove, Novo Nordisk and Oregon National Primate Research Center, USA

Utility of Non-Human Primates for New Target Validation

Jin-Long Chen, NGM Biopharmaceuticals, Inc., USA

Identification of Novel Mediators of the Beneficial Metabolic Effects of Gastric Bypass

Markus Stoffel, ETH Zürich, Switzerland

Discovery of New RNA-Based Therapeutics for the Treatment of Metabolic Diseases

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

THURSDAY, APRIL 21

Departure